Skip to content
2000
image of An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical Indications

Abstract

The year 2024 witnessed significant advancements in cancer therapy, with the U.S. Food and Drug Administration (FDA) approving 56 anticancer drugs for various malignancies. These approvals encompass 36 organic small molecules and 20 macromolecular monoclonal antibody conjugates, each with distinct mechanisms of action targeting key oncogenic pathways. Among the small molecules, kinase inhibitors such as Ribociclib, Imatinib Mesylate, and Nilotinib Hydrochloride Dihydrate modulate critical signaling cascades, while antimetabolites like Fluorouracil and Pemetrexed Disodium disrupt nucleotide biosynthesis. Other classes include DNA-damaging agents (Mitomycin, Gemcitabine Hydrochloride), immune modulators (Pomalidomide, Lenalidomide), and hormonal antagonists (Abiraterone Acetate, Erleada). The macromolecular therapeutics primarily consist of monoclonal antibody-based agents, such as Keytruda, Tecentriq, and Imfinzi, which enhance immune checkpoint inhibition, and antibody-drug conjugates like Enhertu and Elahere, which deliver cytotoxic payloads with high specificity. This review systematically examines the chemical synthesis, mechanisms of action, and therapeutic indications of these FDA-approved agents, emphasizing their role in improving patient outcomes. By analyzing their structural frameworks and biological targets, we aim to provide insights into current trends in anticancer drug development and potential future directions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266407555251118115842
2026-02-24
2026-03-08

  • From This Site

    /content/journals/ctmc/10.2174/0115680266407555251118115842
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Vaccinations M-S.V.S.P. Trends in FDA-approved cancer therapies. US Pharm. 2023 48 10 14
    [Google Scholar]
  2. Gupta R. Srivastava D. Sahu M. Tiwari S. Ambasta R.K. Kumar P. Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Mol. Divers. 2021 25 3 1315 1360 10.1007/s11030‑021‑10217‑3 33844136
    [Google Scholar]
  3. Tanoli Z. Vähä-Koskela M. Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin. Drug Discov. 2021 16 9 977 989 10.1080/17460441.2021.1883585 33543671
    [Google Scholar]
  4. Kar S. Sanderson H. Roy K. Benfenati E. Leszczynski J. Green chemistry in the synthesis of pharmaceuticals. Chem. Rev. 2022 122 3 3637 3710 10.1021/acs.chemrev.1c00631 34910451
    [Google Scholar]
  5. Dutt R. Garg V. Khatri N. Madan A.K. Phytochemicals in anticancer drug development. Anticancer. Agents Med. Chem. 2019 19 2 172 183 10.2174/1871520618666181106115802
    [Google Scholar]
  6. Sharma S. Das J. Braje W.M. Dash A.K. Handa S. A glimpse into green chemistry practices in the pharmaceutical industry. ChemSusChem 2020 13 11 2859 2875 10.1002/cssc.202000317 32212245
    [Google Scholar]
  7. Wang Y. Chen Y. Ji D.K. Huang Y. Huang W. Dong X. Yao D. Wang D. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer. J. Nanobiotechnology 2024 22 1 461 10.1186/s12951‑024‑02727‑7 39090622
    [Google Scholar]
  8. Mahjour B. Shen Y. Cernak T. Ultrahigh-throughput experimentation for information-rich chemical synthesis. Acc. Chem. Res. 2021 54 10 2337 2346 10.1021/acs.accounts.1c00119 33891404
    [Google Scholar]
  9. Tiwari V.K. Jaiswal M.K. Rajkhowa S. Singh S.K. Growing Opportunities of Click Chemistry in Drug Development Click Chemistry. Cham Springer 2024 479 528
    [Google Scholar]
  10. Buchanan D. Pham A.M. Singh S.K. Panda S.S. Molecular hybridization of alkaloids using 1, 2, 3-triazole-based click chemistry. Molecules 2023 28 22 7593 10.3390/molecules28227593 38005315
    [Google Scholar]
  11. Tong F. Lu Y. Ma H.F. Shen J. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis. Heliyon 2024 10 11 31583 10.1016/j.heliyon.2024.e31583 38832268
    [Google Scholar]
  12. Burne R. Balu S. Guérin A. Bungay R. Sin R. Paul M.L. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors. J. Med. Econ. 2021 24 1 806 815 10.1080/13696998.2021.1939705 34098827
    [Google Scholar]
  13. Poratti M. Marzaro G. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. Eur. J. Med. Chem. 2019 172 143 153 10.1016/j.ejmech.2019.03.064 30978559
    [Google Scholar]
  14. Li Y. Du R. Nie Y. Wang T. Ma Y. Fan Y. Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity. Bioorg. Chem. 2021 109 104717 10.1016/j.bioorg.2021.104717 33647744
    [Google Scholar]
  15. Nerella Bhavani, Reddy, M.S. Imatinib mesylate: Recent drug used in oncology. GSC Biol. Pharm. Sci. 2023 22 2 173 186 10.30574/gscbps.2023.22.2.0059
    [Google Scholar]
  16. Lee H. Basso I.N. Kim D.D.H. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int. J. Hematol. 2021 113 5 632 641 10.1007/s12185‑021‑03126‑6 33772728
    [Google Scholar]
  17. Loscocco F. Visani G. Galimberti S. Curti A. Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front. Oncol. 2019 9 939 10.3389/fonc.2019.00939 31612105
    [Google Scholar]
  18. Shen X. He X. Yang J. Wu S. Zhan H. Method for synthesizing Imatinib. U.S. patent 12/866,776 2013
    [Google Scholar]
  19. Kovalev I.S. Zyryanov G.V. Santra S. Majee A. Varaksin M.V. Charushin V.N. Folic acid antimetabolites (antifolates): A brief review on synthetic strategies and application opportunities. Molecules 2022 27 19 6229 10.3390/molecules27196229 36234766
    [Google Scholar]
  20. de Rouw N. Piet B. Derijks H.J. van den Heuvel M.M. ter Heine R. Mechanisms, management and prevention of pemetrexed-related toxicity. Drug Saf. 2021 44 12 1271 1281 10.1007/s40264‑021‑01135‑2 34741752
    [Google Scholar]
  21. Mohiuddin M. Kimura H. Sone T. Watanabe S. Matsuoka H. Saeki K. Terada N. Abo M. Kasahara K. Abstract LB100: Pemetrexed disodium heptahydrate and cisplatin have distinctive growth inhibitory effects in monotherapy and combination therapy on A549 cells. Cancer Res. 2021 81 13 Suppl. LB100 10.1158/1538‑7445.AM2021‑LB100
    [Google Scholar]
  22. Cao Y. Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma. Front. Med. 2022 9 917485 10.3389/fmed.2022.917485
    [Google Scholar]
  23. Jaggavarapu R.M.R. Muvvala V. Ghojala V. Babu H.S. Cheedarala R.K. Facile synthetic protocols for the preparation of new impurities in pemetrexed disodium heptahydrate as an anti-cancer drug. Curr. Org. Synth. 2022 19 1 2 9 10.2174/1570179418666210114145914 33459237
    [Google Scholar]
  24. Qi H. Wen J. Li L. Bai R. Chen L. Wang D. An efficient synthesis of pemetrexed disodium. J. Heterocycl. Chem. 2015 52 5 1565 1569 10.1002/jhet.2164
    [Google Scholar]
  25. Lian T. Li C. Wang H. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations. Cancer Treat. Rev. 2019 81 101907 10.1016/j.ctrv.2019.101907 31715422
    [Google Scholar]
  26. Zhu J. Li C. Yang H. Guo X. Huang T. Han W. Computational study on the effect of inactivating/activating mutations on the inhibition of MEK1 by trametinib. Int. J. Mol. Sci. 2020 21 6 2167 10.3390/ijms21062167 32245216
    [Google Scholar]
  27. Hoffner B. Benchich K. Trametinib: A targeted therapy in metastatic melanoma. J. Adv. Pract. Oncol. 2018 9 7 741 745 31249721
    [Google Scholar]
  28. Ballantyne A.D. Garnock-Jones K.P. Dabrafenib: First global approval. Drugs 2013 73 12 1367 1376 10.1007/s40265‑013‑0095‑2 23881668
    [Google Scholar]
  29. Flaherty K.T. Infante J.R. Daud A. Gonzalez R. Kefford R.F. Sosman J. Hamid O. Schuchter L. Cebon J. Ibrahim N. Kudchadkar R. Burris H.A. Falchook G. Algazi A. Lewis K. Long G.V. Puzanov I. Lebowitz P. Singh A. Little S. Sun P. Allred A. Ouellet D. Kim K.B. Patel K. Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012 367 18 1694 1703 10.1056/NEJMoa1210093 23020132
    [Google Scholar]
  30. Talloa D. Triarico S. Agresti P. Mastrangelo S. Attinà G. Romano A. Maurizi P. Ruggiero A. BRAF and MEK targeted therapies in pediatric central nervous system tumors. Cancers 2022 14 17 4264 10.3390/cancers14174264 36077798
    [Google Scholar]
  31. Haiping L. Sheng X. Sheng X. Crystal form of Dabrafenib mesylate and preparation method thereof. US patent 9884856B2, 2018
  32. Utsunomiya T. Tanaka T. Utsunomiya H. Umesaki N. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int. J. Oncol. 2008 32 5 991 1000 10.3892/ijo.32.5.991 18425325
    [Google Scholar]
  33. Wong D.V.T. Ribeiro-Filho H.V. Wanderley C.W.S. Leite C.A.V.G. Lima J.B. Assef A.N.B. Cajado A.G. Batista G.L.P. González R.H. Silva K.O. Borges L.P.C. Alencar N.M.N. Wilke D.V. Cunha T.M. Figueira A.C.M. Cunha F.Q. Lima-Júnior R.C.P. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemother. Pharmacol. 2019 84 2 287 298 10.1007/s00280‑019‑03844‑z 31011814
    [Google Scholar]
  34. Páez D. Tobeña M. Fernández-Plana J. Sebio A. Virgili A.C. Cirera L. Barnadas A. Riera P. Sullivan I. Salazar J. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br. J. Cancer 2019 120 2 190 195 10.1038/s41416‑018‑0348‑7 30585257
    [Google Scholar]
  35. Vishnukant B. Purohit P. Paparao K. Process for the preparation of irinotecan hydrochloride trihydrate. U.S. patent 20080182990, 2008
  36. Ciołczyk-Wierzbicka D. Gil D. Zarzycka M. Laidler P. mTOR inhibitor everolimus reduces invasiveness of melanoma cells. Hum. Cell 2020 33 1 88 97 10.1007/s13577‑019‑00270‑4 31586300
    [Google Scholar]
  37. Ciołczyk-Wierzbicka D. Zarzycka M. Gil D. Laidler P. mTOR inhibitor Everolimus-induced apoptosis in melanoma cells. J. Cell Commun. Signal. 2019 13 3 357 368 10.1007/s12079‑019‑00510‑0 30848427
    [Google Scholar]
  38. Maracci C. Motta S. Romagnoli A. Costantino M. Perego P. Di Marino D. The mTOR/4E-BP1/eIF4E signalling pathway as a source of cancer drug targets. Curr. Med. Chem. 2022 29 20 3501 3529 10.2174/0929867329666220224112042 35209811
    [Google Scholar]
  39. Akbari Dilmaghani N. Safaroghli-Azar A. Pourbagheri-Sigaroodi A. Bashash D. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life 2021 73 4 618 642 10.1002/iub.2446 33476088
    [Google Scholar]
  40. Rao D.R. Malhotra G. Pullela V.S. Acharya V.P. Process for the synthesis of everolimus and intermediates thereof. U.S. patent 9938297, 2018
  41. Iacovelli R. Arduini D. Ciccarese C. Pierconti F. Strusi A. Piro G. Carbone C. Foschi N. Daniele G. Tortora G. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. Crit. Rev. Oncol. Hematol. 2022 176 103750 10.1016/j.critrevonc.2022.103750 35728738
    [Google Scholar]
  42. Liao C. Hu L. Zhang Q. Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma. Nat. Rev. Urol. 2024 21 11 662 675 10.1038/s41585‑024‑00876‑w 38698165
    [Google Scholar]
  43. Visweswaran V. Pavithran K. Belzutifan: A narrative drug review. Curr. Drug Res. Rev. 2022 14 2 88 95 10.2174/2589977514666220401094724 35366789
    [Google Scholar]
  44. Nguyen C.B. Oh E. Bahar P. Vaishampayan U.N. Else T. Alva A.S. Novel approaches with hif-2α Targeted therapies in metastatic renal cell carcinoma. Cancers 2024 16 3 601 10.3390/cancers16030601 38339352
    [Google Scholar]
  45. Le D.N. Johnson H.C. Lam Y. Sun C. Cheng L. Belyk K.M. Enantio- and diastereoselective total synthesis of belzutifan enabled by rh-catalyzed hydrogenation. Org. Lett. 2024 26 19 4059 4064 10.1021/acs.orglett.4c00982 38709100
    [Google Scholar]
  46. Lalic H. Aurer I. Batinic D. Visnjic D. Smoljo T. Babic A. Bendamustine: A review of pharmacology, clinical use and immunological effects.(Review) Oncol. Rep. 2022 47 6 114 10.3892/or.2022.8325 35506458
    [Google Scholar]
  47. Lee Y.T. Tan Y.J. Oon C.E. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharm. Sin. B 2023 13 2 478 497 10.1016/j.apsb.2022.09.010 36873180
    [Google Scholar]
  48. Singh R. Malhotra A. Bansal R. Synthetic cytotoxic drugs as cancer chemotherapeutic agents Medicinal chemistry of chemotherapeutic agents. Amsterdam, Netherlands Elsevier 2023 499 537 10.1016/B978‑0‑323‑90575‑6.00010‑7
    [Google Scholar]
  49. Erol A. Akpınar F. Muti M. Electrochemical determination of anticancer drug Bendamustine and its interaction with double strand DNA in the absence and presence of quercetin. Colloids Surf. B Biointerfaces 2021 205 111884 10.1016/j.colsurfb.2021.111884 34102529
    [Google Scholar]
  50. Desai J. Fong P. Moreno V. Frentzas S. Meniawy T. Markman B. Voskoboynik M. Rahman T. Budha N. Wu J. Marlow J. Yang S. Calvo E. Martin-Liberal J. A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. Br. J. Cancer 2023 128 8 1418 1428 10.1038/s41416‑022‑02128‑3 36797356
    [Google Scholar]
  51. Shen L. Guo J. Zhang Q. Pan H. Yuan Y. Bai Y. Liu T. Zhou Q. Zhao J. Shu Y. Huang X. Wang S. Wang J. Zhou A. Ye D. Sun T. Gao Y. Yang S. Wang Z. Li J. Wu Y.L. Tislelizumab in Chinese patients with advanced solid tumors: An open-label, non-comparative, phase 1/2 study. J. Immunother. Cancer 2020 8 1 000437 10.1136/jitc‑2019‑000437 32561638
    [Google Scholar]
  52. Yao J. Tan X. Sha Y. Chen Y. Chen R. Shi D. An updated review of immunotherapy in esophageal cancer: PD-L1 footprint. Cent. Eur. J. Immunol. 2024 49 1 77 90 10.5114/ceji.2024.139269 38812606
    [Google Scholar]
  53. Yanagisawa T. Kawada T. Rajwa P. Mostafaei H. Motlagh R.S. Quhal F. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis Urologic Oncology: Seminars and Original Investigations. Amsterdam, Netherlands Elsevier 2023
    [Google Scholar]
  54. Eryilmaz I.E. Egeli U. Cecener G. Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes. Cancer Biol. Ther. 2024 25 1 2329368 10.1080/15384047.2024.2329368 38485703
    [Google Scholar]
  55. Sousa-Pimenta M. Estevinho L.M. Szopa A. Basit M. Khan K. Armaghan M. Ibrayeva M. Sönmez Gürer E. Calina D. Hano C. Sharifi-Rad J. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: Paclitaxel, docetaxel, and cabazitaxel. Front. Pharmacol. 2023 14 1157306 10.3389/fphar.2023.1157306 37229270
    [Google Scholar]
  56. Manda A. Komati S.K. Basu D. Senadi G.C. Maruthapillai A. Bandichhor R. Synthesis, characterization, and control strategies for cabazitaxel-related substances at scale. Org. Process Res. Dev. 2025 29 1 173 180 10.1021/acs.oprd.4c00414
    [Google Scholar]
  57. Short N.J. Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Am. J. Hematol. 2022 97 12 1616 1626 10.1002/ajh.26667 35871436
    [Google Scholar]
  58. Gulei D. Moisoiu V. Kegyes D. Drula R. Iluta S. Tigu A.B. Nistor M. Jitaru C. Bancos A. Rotariu P. Popovici C. Dima D. Tomai R. Rus I. Constantinescu C. Munteanu R. Cenariu D. Sezerman U. Zdrenghea M. Cermak J. Einsele H. Ghiaur G. Tomuleasa C. RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high‐grade myelodysplastic syndromes. J. Cell. Mol. Med. 2024 28 18 70078 10.1111/jcmm.70078 39334509
    [Google Scholar]
  59. Xia Y. Chen Q. Liu H.N. Chi Y. Zhu Y. Shan L.S. Dai B. Wu L. Shi X. Synthetic routes and clinical application of new drugs approved by EMA during 2023. Eur. J. Med. Chem. 2024 277 116762 10.1016/j.ejmech.2024.116762 39151275
    [Google Scholar]
  60. Akbar S. Raza A. Mohsin R. Kanbour A. Qadri S. Parray A. Zar Gul A.R. Philip A. Vijayakumar S. Merhi M. Hydrose S. Inchakalody V.P. Al-Abdulla R. Abualainin W. Sirriya S.A. Al-Bozom I. Uddin S. Khan O.M. Mohamed Ibrahim M.I. Al Homsi U. Dermime S. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. Front. Immunol. 2023 13 1097117 10.3389/fimmu.2022.1097117 36741391
    [Google Scholar]
  61. Rashid M.H. Full-length recombinant antibodies from Escherichia coli: Production, characterization, effector function (Fc) engineering, and clinical evaluation MAbs. United Kingdom Taylor & Francis 2022
    [Google Scholar]
  62. Mandrup O.A. Ong S.C. Lykkemark S. Dinesen A. Rudnik-Jansen I. Dagnæs-Hansen N.F. Andersen J.T. Alvarez-Vallina L. Howard K.A. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun. Biol. 2021 4 1 310 10.1038/s42003‑021‑01790‑2 33686177
    [Google Scholar]
  63. Chiang A.W.T. Baghdassarian H.M. Kellman B.P. Bao B. Sorrentino J.T. Liang C. Kuo C.C. Masson H.O. Lewis N.E. Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy. J. Biomed. Sci. 2021 28 1 50 10.1186/s12929‑021‑00746‑2 34158025
    [Google Scholar]
  64. Kumar A. Singh A.K. Singh H. Thareja S. Kumar P. Regulation of thymidylate synthase: An approach to overcome 5-FU resistance in colorectal cancer. Med. Oncol. 2022 40 1 3 10.1007/s12032‑022‑01864‑z 36308643
    [Google Scholar]
  65. Cortez N. Villegas C. Burgos V. Ortiz L. Cabrera-Pardo J.R. Paz C. Therapeutic potential of chlorogenic acid in chemoresistance and chemoprotection in cancer treatment. Int. J. Mol. Sci. 2024 25 10 5189 10.3390/ijms25105189 38791228
    [Google Scholar]
  66. Jubeen F. Liaqat A. Sultan M. Zafar Iqbal S. Sajid I. Sher F. Green synthesis and biological evaluation of novel 5-fluorouracil derivatives as potent anticancer agents. Saudi Pharm. J. 2019 27 8 1164 1173 10.1016/j.jsps.2019.09.013 31885476
    [Google Scholar]
  67. Nathan M.R. Schmid P. A review of fulvestrant in breast cancer. Oncol. Ther. 2017 5 1 17 29 10.1007/s40487‑017‑0046‑2 28680952
    [Google Scholar]
  68. Spoerke J.M. Gendreau S. Walter K. Qiu J. Wilson T.R. Savage H. Aimi J. Derynck M.K. Chen M. Chan I.T. Amler L.C. Hampton G.M. Johnston S. Krop I. Schmid P. Lackner M.R. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat. Commun. 2016 7 1 11579 10.1038/ncomms11579 27174596
    [Google Scholar]
  69. Chen F-J. Krill S.L. Shmeis R.A. Hepner A. Wescott C. Jaskowski T. Fulvestrant formulations and methods of their use. U.S. patent 18/109,421, 2025
  70. Gonzalez-Ochoa E. Veneziani A.C. Oza A.M. Mirvetuximab soravtansine in platinum-resistant ovarian cancer. Clin. Med. Insights Oncol. 2023 17 11795549231187264 10.1177/11795549231187264 37528890
    [Google Scholar]
  71. Shaukat A. Shakeel L. Khan A. Irfan H. Akilimali A. Addressing the challenge of platinum-resistant ovarian cancer: The role of mirvetuximab soravtansine. Netherlands LWW 2025 1 7
    [Google Scholar]
  72. Nwabufo C.K. Mirvetuximab soravtansine in ovarian cancer therapy: Expert opinion on pharmacological considerations. Cancer Chemother. Pharmacol. 2024 93 2 89 105 10.1007/s00280‑023‑04575‑y 37594572
    [Google Scholar]
  73. Heo Y.A. Mirvetuximab soravtansine: First approval. Drugs 2023 83 3 265 273 10.1007/s40265‑023‑01834‑3 36656533
    [Google Scholar]
  74. Nakagawa-Saito Y. Mitobe Y. Togashi K. Suzuki S. Sugai A. Kitanaka C. Okada M. Givinostat inhibition of sp1-dependent MGMT expression sensitizes glioma stem cells to temozolomide. Anticancer Res. 2023 43 3 1131 1138 10.21873/anticanres.16258 36854532
    [Google Scholar]
  75. Lamb Y.N. Givinostat: First approval. Drugs 2024 84 7 849 856 10.1007/s40265‑024‑02052‑1 38967716
    [Google Scholar]
  76. Avalos M. Babiano R. Cintas P. Fuentes J. Jimenez J.L. Palacios J.C. Reaction of glycosylisothiocyanates with 2-chloroethylamine. Synthesis and structure of N-nucleoside analogues. Nucleosides Nucleotides 1990 9 1 137 149 10.1080/07328319008045117
    [Google Scholar]
  77. Roozitalab G. Abedi B. Imani S. Farghadani R. Jabbarzadeh Kaboli P. Comprehensive assessment of TECENTRIQ® and OPDIVO®: Analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma. Cancer Metastasis Rev. 2024 43 3 889 918 10.1007/s10555‑024‑10174‑x 38409546
    [Google Scholar]
  78. Ratner M. Genentech’s PD-L1 agent approved for bladder cancer. New York Nature Publishing 2016
    [Google Scholar]
  79. Kuyucu A.Z. Sayili D. Orkut R. Mert O. Tarman İ.O. Lulaci B. Sencer A.M. Pekmezci A.K. Avci M.E. Kalyoncu S. Inan M. Cell line development and bioreactor process optimization for an atezolizumab biosimilar.Biotechnol. Appl. Biochem. 2024 bab.2704 10.1002/bab.2704 39623595
    [Google Scholar]
  80. Mizuno T. Katsuya Y. Sato J. Koyama T. Shimizu T. Yamamoto N. Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front. Oncol. 2022 12 925938 10.3389/fonc.2022.925938 36091105
    [Google Scholar]
  81. Keam S.J. Tremelimumab: First approval. Drugs 2023 83 1 93 102 10.1007/s40265‑022‑01827‑8 36571670
    [Google Scholar]
  82. Pan B. Larson P. Bolla A.C. A survey of approved PD1/PD-L1 immune checkpoint inhibitors landscape in the United States and Europe. Crit. Rev. Oncol. Hematol. 2021 163 103314 10.1016/j.critrevonc.2021.103314
    [Google Scholar]
  83. Boisgerault N. Bertrand P. Inside PD-1/PD-L1,2 with their inhibitors. Eur. J. Med. Chem. 2023 256 115465 10.1016/j.ejmech.2023.115465 37196547
    [Google Scholar]
  84. Kanp T. Dhuri A.M.B. Rode K. Aalhate M. Paul P. Nair R. Singh P.K. Exploring the potential of nanocarriers for cancer immunotherapy: Insights into mechanism, nanocarriers, and regulatory perspectives. ACS Appl. Bio Mater. 2025 8 1 108 138 10.1021/acsabm.4c01797 39791993
    [Google Scholar]
  85. Sheikh M. Jirvankar P. Innovative immunotherapeutic strategies for gastric cancer: A comprehensive review. AIMS Allergy Immunol. 2025 9 1 27 55 10.3934/Allergy.2025003
    [Google Scholar]
  86. Sun Q. Hong S. Glycoscience in advancing pd-1/pd-l1-axis-targeted tumor immunotherapy. Int. J. Mol. Sci. 2025 26 3 1238 10.3390/ijms26031238 39941004
    [Google Scholar]
  87. Kibble A. 43rd annual congress of the european society for medical oncology (ESMO). Munich, germany-october 19-23, 2018. Drugs Future 2018 43 12 10.1358/dof.2018.043.12.2921059
    [Google Scholar]
  88. Sanmamed M.F. Berraondo P. Rodriguez-Ruiz M.E. Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat. Can. 2022 3 6 665 680 10.1038/s43018‑022‑00401‑1 35764745
    [Google Scholar]
  89. Dasanu C.A. Mann S.K. Baidya M. Mdluli X.P. Stapleton A.E. Codreanu I. Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: Latest research findings and systematic analysis. Expert Opin. Pharmacother. 2024 25 11 1525 1540 10.1080/14656566.2024.2390121 39109526
    [Google Scholar]
  90. Alsuhebany N. Pan C. Holovac E. Do B. McBride A. Zanubrutinib in mantle cell lymphoma management: A comprehensive review. Blood Lymphat. Cancer 2023 13 67 76 10.2147/BLCTT.S426588 38034984
    [Google Scholar]
  91. Manfredi A. Bertolotti M. Grande V. Novo B. Process for the preparation of zanubrutinib. U.S. patent 18/697,596 2024
  92. Li Z. Wrangle J. He K. Sprent J. Rubinstein M.P. IL-15: From discovery to FDA approva. J. Hemat. Oncol. 2025 18 1 19 23 10.1186/s13045‑025‑01664‑8
    [Google Scholar]
  93. Fu Y. Tang R. Zhao X. Engineering cytokines for cancer immunotherapy: A systematic review. Front. Immunol. 2023 14 1218082 10.3389/fimmu.2023.1218082 37483629
    [Google Scholar]
  94. Chamie K. Chang S.S. Rosser C.J. Kramolowski E. Gonzalgo M.L. Sexton W.J. Spilman P. Sender L. Reddy S. Soon-Shiong P. N-803 plus BCG treatment for BCG-naïve or-unresponsive non-muscle invasive bladder cancer: A plain language review. Future Oncol. 2024 20 31 2307 2317 10.1080/14796694.2024.2363744 38953850
    [Google Scholar]
  95. Biala G. Kedzierska E. Kruk-Slomka M. Orzelska-Gorka J. Hmaidan S. Skrok A. Kaminski J. Havrankova E. Nadaska D. Malik I. Research in the field of drug design and development. Pharmaceuticals 2023 16 9 1283 10.3390/ph16091283 37765091
    [Google Scholar]
  96. Plata A. Guerrero-Ramos F. Garcia C. González-Díaz A. Gonzalez-Valcárcel I. de la Morena J.M. Díaz-Goizueta F.J. del Álamo J.F. Gonzalo V. Montero J. Sousa-Escandón A. León J. Pontones J.L. Delgado F. Adriazola M. Pascual Á. Calleja J. Ruano A. Martínez-Piñeiro L. Angulo J.C. Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain. J. Clin. Med. 2021 10 21 5105 10.3390/jcm10215105 34768625
    [Google Scholar]
  97. Guerrero-Ramos F. González-Padilla D.A. González-Díaz A. de la Rosa-Kehrmann F. Rodríguez-Antolín A. Inman B.A. Villacampa-Aubá F. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: Results of the HIVEC-HR randomized clinical trial. World J. Urol. 2022 40 4 999 1004 10.1007/s00345‑022‑03928‑1 35037963
    [Google Scholar]
  98. Zhang Y. Zhao Y. Gao X. Jiang W. Li Z. Yao Q. Yang F. Wang F. Liu J. Kinetic model of the enzymatic Michael addition for synthesis of mitomycin analogs catalyzed by immobilized lipase from T. laibacchii. Molecular Catalysis 2019 466 146 156 10.1016/j.mcat.2019.01.017
    [Google Scholar]
  99. Leenhardt F. Alexandre M. Jacot W. Alpelisib for the treatment of PIK3CA -mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. Expert Opin. Pharmacother. 2021 22 6 667 675 10.1080/14656566.2021.1873952 33622114
    [Google Scholar]
  100. Browne I.M. Okines A.F.C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast Cancer. Cancers 2024 16 12 2259 10.3390/cancers16122259 38927964
    [Google Scholar]
  101. Jia W. Luo S. Guo H. Kong D. Development of PI3Kα inhibitors for tumor therapy. J. Biomol. Struct. Dyn. 2023 41 17 8587 8604 10.1080/07391102.2022.2132293 36221910
    [Google Scholar]
  102. Johariya V. Sharma S. Mali S.N. Banik B.K. Reviewing the synthesis and clinical application of fda-approved anticancer medications. Curr. Top. Med. Chem. 2024 24 26 2255 2273 10.2174/0115680266321816240822060818 39248066
    [Google Scholar]
  103. Rai T. Kaushik N. Malviya R. Sharma P.K. A review on marine source as anticancer agents. J. Asian Nat. Prod. Res. 2024 26 4 415 451 10.1080/10286020.2023.2249825 37675579
    [Google Scholar]
  104. Wozniak A. Boeckx B. Modave E. Weaver A. Lambrechts D. Littlefield B.A. Schöffski P. Molecular biomarkers of response to eribulin in patients with leiomyosarcoma. Clin. Cancer Res. 2021 27 11 3106 3115 10.1158/1078‑0432.CCR‑20‑4315 33795257
    [Google Scholar]
  105. Phillips E. Jones R.L. Huang P. Digklia A. Efficacy of eribulin in soft tissue sarcomas. Front. Pharmacol. 2022 13 869754 10.3389/fphar.2022.869754 35444542
    [Google Scholar]
  106. Qiu X. Xu T. Zhiwei Z. Ge J. Xinwei L. Synthesis of eribulin mesylate. U.S. patent 11,697,655, 2023
  107. Kang C. Trastuzumab deruxtecan: A review in gastric or gastro-oesophageal junction adenocarcinoma. Target. Oncol. 2023 18 6 981 989 10.1007/s11523‑023‑00998‑y 37787931
    [Google Scholar]
  108. Siddiqui T. Rani P. Ashraf T. Ellahi A. Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer. Ann. Med. Surg. 2022 82 104665 10.1016/j.amsu.2022.104665 36268293
    [Google Scholar]
  109. Timmins P. Industry update: The latest developments in the field of therapeutic delivery, August 2022. Ther. Deliv. 2022 13 9 429 444 10.4155/tde‑2022‑0053
    [Google Scholar]
  110. Della Corte C.M. Morgillo F. Rethinking treatment for RET-altered lung and thyroid cancers: Selpercatinib approval by the EMA. ESMO Open 2021 6 1 100041 10.1016/j.esmoop.2020.100041 33477006
    [Google Scholar]
  111. Hughes D.L. Review of synthetic routes and crystalline forms of the oncology drugs capmatinib, selpercatinib, and pralsetinib. Org. Process Res. Dev. 2021 25 10 2192 2204 10.1021/acs.oprd.1c00282
    [Google Scholar]
  112. Conroy R. FDA approves melphalan injection in hepatic-dominant uveal melanoma. Cancer Net 2023
    [Google Scholar]
  113. Park B. Hepzato kit approved for unresectable hepatic-dominant metastatic uveal melanoma. In: Cancer Net; 2023
    [Google Scholar]
  114. Li Y. DNA adducts in cancer chemotherapy. J. Med. Chem. 2024 67 7 5113 5143 10.1021/acs.jmedchem.3c02476 38552031
    [Google Scholar]
  115. Baines A.C. Kanapuru B. Zhao J. Price L.S.L. Zheng N. Konicki R. Manning M.L. Gehrke B.J. Theoret M.R. Gormley N.J. FDA Approval Summary: Teclistamab–a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma. Clin. Cancer Res. 2024 30 24 5515 5520 10.1158/1078‑0432.CCR‑24‑1872 39412823
    [Google Scholar]
  116. Kang C. Teclistamab: First approval. Drugs 2022 82 16 1613 1619 10.1007/s40265‑022‑01793‑1 36352205
    [Google Scholar]
  117. Deeks E.D. Asciminib: First approval. Drugs 2022 82 2 219 226 10.1007/s40265‑021‑01662‑3 35041175
    [Google Scholar]
  118. Monestime S. Al Sagheer T. Tadros M. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation. Am. J. Health Syst. Pharm. 2023 80 2 36 43 10.1093/ajhp/zxac286 36197958
    [Google Scholar]
  119. Shah U. Patel P. Patel A. Gajjar D. Patel M. Solanki N. Patel S. Patel A. Maheshwari R. Asciminib - ABL kinase inhibitor in the treatment of philadelphia chromosome positive chronic myeloid leukemia: Chemistry and pharmacology perspectives. Mini Rev. Org. Chem. 2025 22 2 177 188 10.2174/0118756298270515231010062046
    [Google Scholar]
  120. Wyrwicz L. Rodríguez Sánchez C.A. Sánchez-Rovira P. Lewis S. Sandschafer D. San T. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union. Future Oncol. 2024 20 13 821 832 10.2217/fon‑2023‑0421 38305004
    [Google Scholar]
  121. Fernandes S. Cassani M. Cavalieri F. Forte G. Caruso F. Emerging strategies for immunotherapy of solid tumors using lipid‐based nanoparticles. Adv. Sci. 2024 11 8 2305769 10.1002/advs.202305769 38054651
    [Google Scholar]
  122. Fitch R. Bowman D. Donovan M. Prestrelski S. Abstract LB024: Pharmacokinetics of a novel viscoelastic suspension of trastuzumab biosimilar for high-concentration, low-volume subcutaneous injection. Cancer Res. 2023 83 8 Suppl. LB024 10.1158/1538‑7445.AM2023‑LB024
    [Google Scholar]
  123. Heron M.J. Zhu K.J. Zhu L. Khong J. Mundy L.R. Habibi M. Broderick K.P. Breast cancer immunotherapy: A clinical review for the plastic surgeon. Plast. Reconstr. Surg. Glob. Open 2024 12 6 5915 10.1097/GOX.0000000000005915 38911573
    [Google Scholar]
  124. Pascoe R.D. Kim Y. Rhodes A. Ong J. Tumpach C. Gubser C. Chang J.J. McMahon J.H. Lewin S.R. Rasmussen T.A. Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir. J. Virol. 2025 99 3 e01676 e24 10.1128/jvi.01676‑24 39902962
    [Google Scholar]
  125. Cippitelli M. Stabile H. Kosta A. Petillo S. Gismondi A. Santoni A. Fionda C. Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: Better to lose than to find them. Int. J. Mol. Sci. 2021 22 3 1103 10.3390/ijms22031103 33499314
    [Google Scholar]
  126. Huang D. Shen C. Wang W. Huang L. Ni F. Li J. New synthesis route for the preparation of pomalidomide. Synth. Commun. 2016 46 16 1343 1348 10.1080/00397911.2016.1189574
    [Google Scholar]
  127. Abdo E.L. Ajib I. El Mounzer J. Husseini M. Kalaoun G. Matta T.M. Mosleh R. Nasr F. Richani N. Khalil A. Shayya A. Ghanem H. Faour W.H. Molecular biology of the novel anticancer medications: A focus on kinases inhibitors, biologics and CAR T-cell therapy. Inflamm. Res. 2025 74 1 41 10.1007/s00011‑025‑02008‑5 39960501
    [Google Scholar]
  128. Hultmark S. Modeling normal and malignant hematopoiesis in vitro To screen for extrinsic regulators and differentiation therapy; Lund University: Ljungbyhed, 2022
    [Google Scholar]
  129. Yousefnia S. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias. Cell Biol. Int. 2021 45 6 1148 1157 10.1002/cbin.11563 33527587
    [Google Scholar]
  130. Chin L. Kumana C.R. Kwong Y.L. Gill H. The development and clinical applications of oral arsenic trioxide for acute promyelocytic leukaemia and other diseases. Pharmaceutics 2022 14 9 1945 10.3390/pharmaceutics14091945 36145693
    [Google Scholar]
  131. Kutny M.A. Alonzo T.A. Abla O. Rajpurkar M. Gerbing R.B. Wang Y.C. Hirsch B.A. Raimondi S. Kahwash S. Hardy K.K. Hardy S. Meshinchi S. Gamis A.S. Kolb E.A. Feusner J.H. Gregory J. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: A report from the children’s oncology group AAML1331 trial. JAMA Oncol. 2022 8 1 79 87 10.1001/jamaoncol.2021.5206 34762093
    [Google Scholar]
  132. Zhang Z. Liu H. Zhou H. Zhu X. Zhao Z. Chi X. Shan H. Gao J. A facile route to core–shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment. Nanoscale 2016 8 7 4373 4380 10.1039/C5NR07860A 26840759
    [Google Scholar]
  133. Alanazi W.A. Alanazi A.S. El-Nagar D.M. Aljuraybah A.M. Alsanea S. Alharbi M. Mechanism underlying triple VEGFR inhibitor tivozanib-induced hypertension in mice model. Pharmaceuticals 2023 16 2 295 10.3390/ph16020295 37259438
    [Google Scholar]
  134. Beckermann K.E. Asnis-Alibozek A.G. Atkins M.B. Escudier B. Hutson T.E. Kasturi V. McDermott D.F. Pal S.K. Porta C. Rini B.I. Verzoni E. Long-term survival in patients with relapsed/refractory advanced renal cell carcinoma treated with tivozanib: Analysis of the phase III TIVO-3 Trial. Oncologist 2024 29 3 254 262 10.1093/oncolo/oyad348 38262444
    [Google Scholar]
  135. Mao Y. Zhu C. Wang H. Xu J. A new and practical synthesis of tivozanib. Heterocycles 2016 92 10 1882 1887 10.3987/COM‑16‑13555
    [Google Scholar]
  136. Mellinghoff I.K. Penas-Prado M. Peters K.B. Burris H.A. Maher E.A. Janku F. Cote G.M. de la Fuente M.I. Clarke J.L. Ellingson B.M. Chun S. Young R.J. Liu H. Choe S. Lu M. Le K. Hassan I. Steelman L. Pandya S.S. Cloughesy T.F. Wen P.Y. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin. Cancer Res. 2021 27 16 4491 4499 10.1158/1078‑0432.CCR‑21‑0611 34078652
    [Google Scholar]
  137. Tawfik H.O. Mousa M.H.A. Zaky M.Y. El-Dessouki A.M. Sharaky M. Abdullah O. El-Hamamsy M.H. Al-Karmalawy A.A. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations. Bioorg. Chem. 2024 149 107483 10.1016/j.bioorg.2024.107483 38805913
    [Google Scholar]
  138. Haque N. Parveen S. Tang T. Wei J. Huang Z. Marine natural products in clinical use. Mar. Drugs 2022 20 8 528 10.3390/md20080528 36005531
    [Google Scholar]
  139. Zhao D. Ren J. Wang Q. Zhang Y. Synthesis of deuterium-labeled nelarabine and its active ingredient, ara-G. J. Radioanal. Nucl. Chem. 2020 325 1 47 55 10.1007/s10967‑020‑07193‑7
    [Google Scholar]
  140. Ali E. Ellahi A. Adil M. Shaikh A. Huda Z. Jemperli (Dostarlimab-gxly): An unprecedented cancer trial. Ann. Med. Surg. 2022 79 104047 10.1016/j.amsu.2022.104047 35860105
    [Google Scholar]
  141. Haarberg S. Dostarlimab-gxly (Jemperli™). Oncol. Times 2022 44 18 8 10.1097/01.COT.0000884668.75921.99
    [Google Scholar]
  142. Guirguis A.A. Ebert B.L. Lenalidomide: Deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr. Opin. Cell Biol. 2015 37 61 67 10.1016/j.ceb.2015.10.004 26512454
    [Google Scholar]
  143. Gore V.G. Shukla V.K. Bhandari S.S. Hasbe S. Process for the preparation of lenalidomide. U.S. patent 8,946,265, 2015
  144. Fruchtman H. Avigan Z.M. Waksal J.A. Brennan N. Mascarenhas J.O. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia 2024 38 5 927 935 10.1038/s41375‑024‑02246‑2 38600315
    [Google Scholar]
  145. Wang L Li R Song C Chen Y Long H Yang L Smallmolecule anti-cancer drugs from 2016 to 2020: Synthesis and clinical application. Nat. Prod Commun., 2021 16 9 1934578X211040326 10.1177/1934578X211040326
    [Google Scholar]
  146. Li C. Wang Y. Gong Y. Zhang T. Huang J. Tan Z. Xue L. Finding an easy way to harmonize: A review of advances in clinical research and combination strategies of EZH2 inhibitors. Clin. Epigenetics 2021 13 1 62 10.1186/s13148‑021‑01045‑1 33761979
    [Google Scholar]
  147. Zeng J. Zhang J. Sun Y. Wang J. Ren C. Banerjee S. Ouyang L. Wang Y. Targeting EZH2 for cancer therapy: From current progress to novel strategies. Eur. J. Med. Chem. 2022 238 114419 10.1016/j.ejmech.2022.114419 35569264
    [Google Scholar]
  148. Smith M.R. Saad F. Chowdhury S. Oudard S. Hadaschik B.A. Graff J.N. Olmos D. Mainwaring P.N. Lee J.Y. Uemura H. De Porre P. Smith A.A. Brookman-May S.D. Li S. Zhang K. Rooney B. Lopez-Gitlitz A. Small E.J. Apalutamide and overall survival in prostate cancer. Eur. Urol. 2021 79 1 150 158 10.1016/j.eururo.2020.08.011 32907777
    [Google Scholar]
  149. Rathkopf D.E. Scher H.I. Apalutamide for the treatment of prostate cancer. Expert Rev. Anticancer Ther. 2018 18 9 823 836 10.1080/14737140.2018.1503954 30101644
    [Google Scholar]
  150. Lee A. Sotorasib: A review in KRAS G12C mutation-positive non-small cell lung cancer. Target. Oncol. 2022 17 6 727 733 10.1007/s11523‑022‑00922‑w 36315377
    [Google Scholar]
  151. Blair H.A. Sotorasib: First approval. Drugs 2021 81 13 1573 1579 10.1007/s40265‑021‑01574‑2 34357500
    [Google Scholar]
  152. Maksimenko A. Caron J. Mougin J. Desmaële D. Couvreur P. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. Int. J. Pharm. 2015 482 1-2 38 46 10.1016/j.ijpharm.2014.11.009 25448549
    [Google Scholar]
  153. Álvarez I Gutiérrez C Rodriguez JF De Lucas A García M Production of drug-releasing biodegradable microporous scaffold impregnated with gemcitabine using a CO₂ foaming process. J. CO₂ Util, 2020 41 101227 10.1016/j.jcou.2020.101227
    [Google Scholar]
  154. Thakur A. Roy A. Ghosh A. Chhabra M. Banerjee S. Abiraterone acetate in the treatment of prostate cancer. Biomed. Pharmacother. 2018 101 211 218 10.1016/j.biopha.2018.02.067
    [Google Scholar]
  155. Lenna R. Di Brisco R. Process for the preparation of abiraterone or abiraterone acetate. EP patent 2890705B1, 2017
  156. Candelaria P.V. Nava M. Daniels-Wells T.R. Penichet M.L. A fully human IgE specific for CD38 as a potential therapy for multiple myeloma. Cancers 2023 15 18 4533 10.3390/cancers15184533 37760502
    [Google Scholar]
  157. Spector M. Sobolov-jaynes S.B. Method of treating multiple myeloma. US patent 18/691,365, 2024
  158. Zhao C. Zhang R. Yang H. Gao Y. Zou Y. Zhang X. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation. Biochem. Pharmacol. 2024 226 116378 10.1016/j.bcp.2024.116378 38908529
    [Google Scholar]
  159. Mandapati A. Lukong K.E. Triple negative breast cancer: Approved treatment options and their mechanisms of action. J. Cancer Res. Clin. Oncol. 2023 149 7 3701 3719 10.1007/s00432‑022‑04189‑6 35976445
    [Google Scholar]
  160. Marque P. Viault M. Anquetil M. Soulet N. Association pertuzumab/trastuzumab en sous-cutané, phesgo®600/600 mg: Quels sont les impacts sur la production, l’administration et la prise en charge des patientes? Pharm. Clin. 2024 59 2 50 10.1016/j.phacli.2024.04.062
    [Google Scholar]
  161. Cattrini C. Castro E. Lozano R. Zanardi E. Rubagotti A. Boccardo F. Olmos D. Current treatment options for metastatic hormone-sensitive prostate cancer. Cancers 2019 11 9 1355 10.3390/cancers11091355 31547436
    [Google Scholar]
  162. Hughes D.L. Review of synthetic routes and crystalline forms of the antiandrogen oncology drugs enzalutamide, apalutamide, and darolutamide. Org. Process Res. Dev. 2020 24 3 347 362 10.1021/acs.oprd.0c00005
    [Google Scholar]
  163. Levêque D. Becker G. Toussaint E. Fornecker L.M. Paillard C. Clinical pharmacokinetics of methotrexate in oncology. Int. J. Pharmacokinet. 2017 2 2 137 147 10.4155/ipk‑2016‑0022
    [Google Scholar]
  164. Rózga K. Błauż A. Moscoh Ayine-Tora D. Puścion E. Hartinger C.G. Plażuk D. Rychlik B. Synthesis and biological properties of ferrocenyl and organic methotrexate derivatives. ACS Omega 2024 9 31 33845 33856 10.1021/acsomega.4c03602 39130602
    [Google Scholar]
  165. Scalzulli E. Carmosino I. Bisegna M.L. Martelli M. Breccia M. CML resistant to 2nd-generation TKIs: Mechanisms, next steps, and new directions. Curr. Hematol. Malig. Rep. 2022 17 6 198 205 10.1007/s11899‑022‑00683‑3 36264428
    [Google Scholar]
  166. Balsat M. Alcazer V. Etienne G. Huguet F. Berger M. Cayssials E. Charbonnier A. Escoffre-Barbe M. Johnson-Ansah H. Legros L. Roy L. Delmer A. Ianotto J.C. Orvain C. Larosa F. Meunier M. Amé S. Andreoli A. Cony-Makhoul P. Morisset S. Tigaud I. Rea D. Nicolini F.E. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia. Leuk. Res. 2023 130 107308 10.1016/j.leukres.2023.107308 37230027
    [Google Scholar]
  167. Philipova I. Mihaylova R. Momekov G. Angelova R. Stavrakov G. Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents. RSC Med. Chem. 2023 14 5 880 889 10.1039/D3MD00030C 37252096
    [Google Scholar]
  168. Izu-Belloso R. Gainza-Apraiz I. Ortiz-Romero P. Servitje-Bedate O. Fernández de Misa-Cabrera R. Peñate Y. Hernandez-Machin B. Estrach-Panella T. Llamas-Velasco M. Yanguas-Bayona J.I. Morillo-Andujar M. Acebo-Mariñas E. Perez-Gala S. Armario-Hita J.C. Sanchez-Sambucety P. Ortiz-Brugues A. Eguren-Michelena C. Bielsa-Marsol I. Lopez-Pestaña A. Blanes-Martinez M. Fernandez-Guarino M. Lopez-Lerma I. Experience with bexarotene to treat cutaneous T-cell lymphomas: A study of the Spanish working group of cutaneous lymphomas. Actas Dermosifiliogr. 2024 115 6 547 554 10.1016/j.ad.2023.12.007 38395224
    [Google Scholar]
  169. Ashraf R. Zahoor A.F. Ali K.G. Nazeer U. Saif M.J. Mansha A. Chaudhry A.R. Irfan A. Development of novel transition metal-catalyzed synthetic approaches for the synthesis of a dihydrobenzofuran nucleus: A review. RSC Advances 2024 14 21 14539 14581 10.1039/D4RA01830C 38708111
    [Google Scholar]
  170. Fung A.S. Graham D.M. Chen E.X. Stockley T.L. Zhang T. Le L.W. Albaba H. Pisters K.M. Bradbury P.A. Trinkaus M. Chan M. Arif S. Zurawska U. Rothenstein J. Zawisza D. Effendi S. Gill S. Sawczak M. Law J.H. Leighl N.B. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer 2021 157 21 29 10.1016/j.lungcan.2021.05.021 34052705
    [Google Scholar]
  171. Ram T. Singh A.K. Kumar A. Singh H. Pathak P. Grishina M. Khalilullah H. Jaremko M. Emwas A.H. Verma A. Kumar P. MEK inhibitors in cancer treatment: Structural insights, regulation, recent advances and future perspectives. RSC Med. Chem. 2023 14 10 1837 1857 10.1039/D3MD00145H 37859720
    [Google Scholar]
  172. Huang S. Liu L. Liu X. Song L. Huang C. Miao L. Development and application of a rapid and sensitive liquid chromatography-mass spectrometry method for simultaneous analysis of cytarabine, cytarabine monophosphate, cytarabine diphosphate and cytarabine triphosphate in the cytosol and nucleus. J. Pharm. Biomed. Anal. 2022 211 114582 10.1016/j.jpba.2022.114582 35101802
    [Google Scholar]
  173. Han S. Xiu M. Li S. Shi Y. Wang X. Lin X. Cai H. Liu Y. He J. Exposure to cytarabine causes side effects on adult development and physiology and induces intestinal damage via apoptosis in Drosophila. Biomed. Pharmacother. 2023 159 114265 10.1016/j.biopha.2023.114265 36652735
    [Google Scholar]
  174. Liu S.C. Wu Y.C. Huang C.M. Hsieh M.S. Huang T.Y. Huang C.S. Hsu T.N. Huang M.S. Lee W.H. Yeh C.T. Lin C.S. Inhibition of Bruton’s tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness. Oncogenesis 2021 10 2 20 10.1038/s41389‑021‑00308‑z 33640903
    [Google Scholar]
  175. Chen S.S. Chiorazzi N. Functional consequences of inhibition of Bruton’s tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Hematol. Oncol. 2023 41 S1 119 128 10.1002/hon.3144 37294973
    [Google Scholar]
  176. Luo Y. Zhang Z. Guo X. Tang X. Li S. Gong G. Gao S. Zhang Y. Lin S. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis. Lung Cancer 2023 184 107319 10.1016/j.lungcan.2023.107319 37597303
    [Google Scholar]
  177. Tao Y. Zhou Y. Tang L. Chen H. Feng Y. Shi Y. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest. New Drugs 2022 40 4 831 840 10.1007/s10637‑022‑01242‑6 35435628
    [Google Scholar]
  178. Lijia L. Guo J. Wang Y. Zhao X. Chen J. Wang Y. Use of ensartinib or salt thereof in treatment of disease carrying MET 14 exon skipping mutation. EP patent 4385510A1, 2024
/content/journals/ctmc/10.2174/0115680266407555251118115842
Loading
An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical Indications
Bentham Science Publishers ; https://doi.org/10.2174/0115680266407555251118115842
/content/journals/ctmc/10.2174/0115680266407555251118115842
/content/journals/ctmc/10.2174/0115680266407555251118115842
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Targeted therapy ; Chemotherapy ; Antibody-drug conjugates ; FDA-approved anticancer drugs ; Small molecule inhibitors ; Monoclonal antibodies ; Kinase inhibitors ; Immune checkpoint inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test